Abstract 4526
Background
Imatinib mesylate is approved in unresectable tumors and has been also proposed in the neoadjuvant setting in order to reduce tumor size and post-operative relapses for difficult to resect DFSP. The aim of this study was to evaluate the long-term results of neoadjuvant imatinib and other TKI used in DFSP.
Methods
The files of all patients with the following criteria seen from 2007 to 2017 in our center were collected in this retrospective study: a/histologically proven primary or recurrent DFSP with COL1A1-PDGFB translocation b/ difficult to treat but surgically manageable as assessed in pluridisciplinary tumor board, c/received first-line neoadjuvant TKI (imatinib, pazopanib). The primary endpoint was long-term progression-free survival (PFS).
Results
27 patients (median 42 years, range: 18-63) were included, of whom 9 (33%) had fibrosarcomatous transformation on pre-TKI biopsy. 10 patients had primary tumors and 17 presented recurrences. Median tumor size was 6 cm (range 3-30). 24 patients received imatinib (median dose= 600mg/day), 3 received pazopanib (median dose= 600mg/day) for a median of 7 months. The best MRI response to ITK treatment before surgery according to RECIST1.1 consisted of complete/partial response (33%) or stability (48%). DFSP was surgically removed in 24 patients (89%) after a median of 7 months and 2 surgeries. Two patients (7%) did not receive surgery because of metastasis progression. One other patient declined surgery. 23 of 24 patients surgically treated were disease-free after 50 months of median follow-up (range 10-133). One patient developed distant metastasis 37 months after the complete surgical resection. The median PFS was 44 months (range 10-133).The histological response localization was mainly patchy (n = 10) or diffuse (n = 7). The median percentage of therapeutic response surface was 65%.Treatment-related adverse events occurred in 23 patients (85%). 4 patients had grade 3 or higher toxicities (2 grade 3 and 4 neutropenia, 1 grade 3 cholestasis, 1 grade 3 nausea) requiring temporary treatment disruption and dose reductions.
Conclusions
TKI are effective neoadjuvant treatment for locally advanced or inoperable DFSP with long-term PFS and few severe adverse events.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3020 - Circulating tumor DNA (ctDNA) analysis depicts mechanisms of resistance and tumor response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)
Presenter: Sandra Ortiz - Cuaran
Session: Poster Display session 1
Resources:
Abstract
1271 - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC).
Presenter: Ryo Itotani
Session: Poster Display session 1
Resources:
Abstract
1132 - Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Presenter: Aaron Cohen
Session: Poster Display session 1
Resources:
Abstract
1502 - An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK Study
Presenter: David Gandara
Session: Poster Display session 1
Resources:
Abstract
3912 - Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumor DNA
Presenter: Wei Fang Hsu
Session: Poster Display session 1
Resources:
Abstract
3856 - Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: a study on circulating tumor DNA
Presenter: Romano Danesi
Session: Poster Display session 1
Resources:
Abstract
1330 - Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer
Presenter: Xiaoxia Chen
Session: Poster Display session 1
Resources:
Abstract
3512 - Carcinoembryonic Antigen of Cerebrospinal Fluid Predict Prognosis of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Presenter: Junjie Zhen
Session: Poster Display session 1
Resources:
Abstract
3852 - Liquid biopsy in clinical pratice of Non-Small-Cell-Lung Cancer (NSCLC): a multi-institutional experience
Presenter: Giovanna De Maglio
Session: Poster Display session 1
Resources:
Abstract
1205 - A Phase III Study Comparing SB8, a Proposed Bevacizumab Biosimilar, and Reference Bevacizumab in Patients with Metastatic or Recurrent Non-squamous NSCLC
Presenter: Martin Reck
Session: Poster Display session 1
Resources:
Abstract